Targeting the anti-apoptotic protein Mcl-1 with the mTOR inhibitor RAD001 sensitizes luminal breast cancers to the Bcl-2/Bcl-xL inhibitor ABT-263

被引：0
|
作者：
Williams, Michelle M. [1 ]
Lee, Linus [1 ]
Morrison, Meghan M. [1 ]
Williams, Andrew J. [1 ]
Sanchez, Violeta [1 ]
Hicks, Donna [1 ]
Cook, Rebecca [1 ]
机构：
[1] Vanderbilt Univ, Nashville, TN 37235 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2015年 / 14卷 / 07期
关键词：
D O I：
10.1158/1538-8514.PI3K14-B09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B09
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells
    Wang, Bin
    Ni, Zhenhong
    Dai, Xufang
    Qin, Liyan
    Li, Xinzhe
    Xu, Liang
    Lian, Jiqin
    He, Fengtian
    MOLECULAR CANCER, 2014, 13
  • [2] The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells
    Bin Wang
    Zhenhong Ni
    Xufang Dai
    Liyan Qin
    Xinzhe Li
    Liang Xu
    Jiqin Lian
    Fengtian He
    Molecular Cancer, 13
  • [3] Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
    Violetta Ritter
    Franziska Krautter
    Diana Klein
    Verena Jendrossek
    Justine Rudner
    Cell Death & Disease, 12
  • [4] Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
    Ritter, Violetta
    Krautter, Franziska
    Klein, Diana
    Jendrossek, Verena
    Rudner, Justine
    CELL DEATH & DISEASE, 2021, 12 (07)
  • [5] New insights into binding of natural chalcones to Bcl-2, Bcl-xL and Mcl-1 anti-apoptotic proteins
    cirin, Dejan
    Krstonosic, Veljko
    JOURNAL OF MOLECULAR STRUCTURE, 2021, 1241
  • [6] Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
    Violetta Ritter
    Franziska Krautter
    Diana Klein
    Verena Jendrossek
    Justine Rudner
    Cell Death & Disease, 13
  • [7] Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on Celecoxib-induced apoptosis
    Rudner, Justine
    Elsaesser, Simon Johannes
    Mueller, Arndt-Christian
    Belka, Claus
    Jendrossek, Verena
    BIOCHEMICAL PHARMACOLOGY, 2010, 79 (01) : 10 - 20
  • [8] ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
    Guan Wang
    Yao Zhan
    Haiqing Wang
    Wenhua Li
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 799 - 805
  • [9] ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
    Wang, Guan
    Zhan, Yao
    Wang, Haiqing
    Li, Wenhua
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 799 - 805
  • [10] mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
    Coffee, Erin M.
    Faber, Anthony C.
    Costa, Carlotta
    Dastur, Anahita
    Ebi, Hiromichi
    Hata, Aaron N.
    Yeo, Alan T.
    Elena, J.
    Song, Youngchul
    Tam, Ah Ting
    Boisvert, Jessica L.
    Milano, Randy J.
    Roper, Jatin
    Kodack, David P.
    Jain, Rakesh K.
    Corcoran, Ryan B.
    Rivera, Miguel N.
    Ramaswamy, Sridhar
    Hung, Kenneth E.
    Benes, Cyril H.
    Engelman, Jeffrey A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345